Durect Corp (DRRX)

0.89
NASDAQ : Health Care
Prev Close 0.90
Day Low/High 0.88 / 0.93
52 Wk Low/High 0.85 / 2.00
Avg Volume 317.60K
Exchange NASDAQ
Shares Outstanding 141.89M
Market Cap 127.70M
EPS -0.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Durect Stock Sees Short Interest Fall 19.6%

Durect Stock Sees Short Interest Fall 19.6%

The most recent short interest data has been released for the 12/30/2016 settlement date, which shows a 686,881 share decrease in total short interest for Durect Corp , to 2,816,491, a decrease of 19.61% since 12/15/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Short Interest In Durect Moves 21.5% Higher

Short Interest In Durect Moves 21.5% Higher

The most recent short interest data has been released for the 10/31/2016 settlement date, which shows a 743,073 share increase in total short interest for Durect Corp , to 4,195,826, an increase of 21.52% since 10/14/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

DURECT Corporation Announces Update On DUR-928 Development Program

DURECT Corporation Announces Update On DUR-928 Development Program

Initial data from Phase 1b study in NASH

5 Stocks Insiders Love Right Now

5 Stocks Insiders Love Right Now

Insiders at these companies are scooping up shares of their own stock lately.

Durect Corp. (DRRX) Stock Tumbles on FDA Opioid Analgesic Drug Rejection

Durect Corp. (DRRX) Stock Tumbles on FDA Opioid Analgesic Drug Rejection

Durect Corp.'s (DRRX) licensee Pain Therapeutics (PTIE) new drug application for an opioid analgesic was denied by the FDA.

5 Big-Volume Stocks You Should Stay Away From -- Plus 2 to Buy

5 Big-Volume Stocks You Should Stay Away From -- Plus 2 to Buy

Here's a technical look at how to trade some of the most active stocks on the market right now.

Interesting DRRX Call Options For April 2017

Interesting DRRX Call Options For April 2017

Investors in Durect Corp saw new options begin trading today, for the April 2017 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 242 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

DURECT Provides REMOXY® Update

DURECT Provides REMOXY® Update

Pain Therapeutics Announced today that an FDA Advisory Committee Meeting for REMOXY® is Not Needed and No Change to September 25, 2016 PDUFA Date

DURECT Announces FDA Advisory Committee Meeting For REMOXY®

DURECT Announces FDA Advisory Committee Meeting For REMOXY®

FDA's Tentative Date for Advisory Committee Meeting is August 5, 2016 and No Change to PDUFA Date of September 25, 2016

Insider Trading Alert - SMLP, DRRX And MDSO Traded By Insiders

Insider Trading Alert - SMLP, DRRX And MDSO Traded By Insiders

Stocks with insider trader activity include SMLP, DRRX and MDSO